Setting the Stage: Immunotherapy’s Impact and EMPOWER-Lung 1 Study Design
Panelists discuss how over the last five years, immunotherapy, particularly PD-1 inhibitors, has revolutionized advanced non-small cell lung cancer (NSCLC) treatment, offering promising first-line therapy options. Prior to the EMPOWER-Lung 1 study, PD-1 inhibitors showed improved survival outcomes as monotherapy. Treatment considerations have since evolved to incorporate patient-specific factors, optimizing therapy based on individual characteristics.
Video content above is prompted by the following:
- Over the last five years, how has the emergence of immunotherapy in advanced NSCLC shifted the treatment paradigm in terms of the use of PD-1 inhibitors as first-line therapy?
- Prior to this study, what was known about the survival outcomes of patients receiving PD-1 inhibitors when used as monotherapy in the treatment of advanced NSCLC?
- How have treatment considerations changed regarding the characteristics of patients receiving PD-1 inhibitors since the initiation of this trial?
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Recent Videos
Related Content
